SRD5A 1 and SRD5A2 are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor Antagonists.

MLA

Xin Gu, et al. “SRD5A 1 and SRD5A2 Are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor Antagonists.” Journal of Urology, vol. 190, no. 2, Aug. 2013, pp. 615–19. EBSCOhost, https://doi.org/10.1016/j.juro.2013.03.024.

APA

Xin Gu, Rong Ha, Tao Huang, Li Wang, Sha Tao, Lu Tian, Zhuo Chen, Yang Jiao, Jian Kang, Siqun Zheng, Jianfeng Xu, Jielin Sun, & Jun Qi. (2013). SRD5A 1 and SRD5A2 are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor Antagonists. Journal of Urology, 190(2), 615–619. https://doi.org/10.1016/j.juro.2013.03.024

Chicago

Xin Gu, Rong Ha, Tao Huang, Li Wang, Sha Tao, Lu Tian, Zhuo Chen, et al. 2013. “SRD5A 1 and SRD5A2 Are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor Antagonists.” Journal of Urology 190 (2): 615–19. doi:10.1016/j.juro.2013.03.024.